Return-Path: Received: from [172.17.86.169] (syn-072-187-255-018.biz.spectrum.com. [72.187.255.18]) by smtp.gmail.com with ESMTPSA id 71dfb90a1353d-56d31bf719bsm7136675e0c.4.2026.03.26.16.29.29 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 26 Mar 2026 16:29:29 -0700 (PDT) Date: Thu, 26 Mar 2026 19:29:23 -0400 From: tjphuhs@gmail.com To: "=?utf-8?Q?oc.tjphuhs=40gmail.com?=" Message-ID: <5f964887-b71e-4988-a9c7-250edf80a1d2@Spark> In-Reply-To: <20260326.220251.2b0745df@mta25> References: <20260326.220251.2b0745df@mta25> Subject: Fwd: Your BPC-157 Experience Could Change FDA policy X-Readdle-Message-ID: 5f964887-b71e-4988-a9c7-250edf80a1d2@Spark MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="69c5c159_107c1e2d_7d92" --69c5c159_107c1e2d_7d92 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline ---------- =46orwarded message ---------- =46rom: Hunter Williams Date: Mar 26, 2026 at 6:02=E2=80=AFPM -0400 To: tjphuhs=40gmail.com Subject: Your BPC-157 Experience Could Change =46DA policy > Just 5 minutes of your time > March 26, 2026 =C2=A0 =7C =C2=A0 Read online > Your BPC-157 Experience Could Change =46DA policy > Just 5 minutes of your time > > > > Happy Thursday=21 > The =46DA classified BPC-157 as a Category 2 bulk drug substance in 202= 3. > Their reasoning=3F Insufficient evidence on whether it causes harm to h= umans. > Meanwhile, hundreds of thousands of people have used BPC-157, including= many of you reading this right now. And most of you walked away with zer= o adverse events and a healed injury. > But as of now, we have no documented way to verify the safety and effic= acy of some of the most common and effective peptides. > Well, hopefully that=E2=80=99s about to change. > > The Project > I've been working on something behind the scenes with a team of heavy h= itters that I'm finally ready to share with you. > It's called the Peptide Safety Initiative. > The =46DA says there isn't enough human safety data on BPC-157 to justi= fy allowing compounding pharmacies to produce it. The published clinical = data are razor-thin. One small pilot study. A couple of retrospective cas= e reviews. No large-scale human trials. > But what does the =46DA not have access to=3F > Your experience. > The real-world experience of the thousands of people who have used BPC-= 157 for gut healing, tendon repair, joint recovery, post-surgical rehab, = and everything in between. > That gap between what regulators see on paper and what our community ha= s experienced firsthand is the entire problem. > So we built a tool to close that gap. > > The Peptide Safety Initiative > We created a structured reporting platform where you can document your = personal experience with BPC-157. The data gets aggregated and de-identif= ied. Then it goes directly to the doctors and researchers working with th= e =46DA on peptide reclassification. > This is a real-world evidence collection effort modeled after the kind = of data regulatory bodies actually take seriously. > There is a commission currently reviewing the Category 2 designation fo= r several peptides. > The doctors on that commission need volume. > They need to show the =46DA that real humans have used this compound, h= ere's what happened, and here's the safety profile across a large populat= ion. > Good, bad, or neutral. All of it matters. > > What You'll Be Asked > The form takes a few minutes. There are two tracks. > If you're a clinician or prescriber, you'll document your professional = experience with BPC-157 across your patient population. > Clinical indications you treated. Objective outcomes you observed. Rout= es of administration, dosing protocols, duration of use, and sourcing. > There's a dedicated adverse event reporting section covering injection = site reactions, fluid retention, hypoglycemia symptoms, cardiac changes, = neuropsychiatric effects, GI issues, and blood pressure fluctuations. > You'll also rate the overall safety profile on a 0 to 10 scale based on= your clinical judgment. > If you're an individual user, you'll share basic demographics (age, sex= , height, weight, ethnicity), what your goal was for using BPC-157, what = results you experienced, your dosing details, and where you sourced it. > You'll go through the same adverse event checklist covering injection s= ite reactions, swelling, hypoglycemia symptoms, heart rate changes, mood = effects, GI distress, and blood pressure changes. You'll rate overall saf= ety on the same 0 to 10 scale. > Both tracks ask whether you discontinued use due to side effects. And b= oth give you space to share additional details like lab values, imaging f= indings, or recovery stories. > Everything is voluntary. Everything is anonymous. > > Why This Matters > The regulatory landscape around peptides is shifting fast. There are pe= ople inside the system right now who are willing to fight for reclassific= ation. But they need ammunition. > Anecdotes in a Reddit thread don't move regulatory bodies, but structur= ed, aggregated real-world evidence from hundreds or thousands of people d= oes. > Think about what we're up against. > The =46DA's position is that there's not enough human data. That's tech= nically true when you look at published clinical trials. But it completel= y ignores the massive real-world evidence base sitting inside this commun= ity. > We can change that. But only if enough people participate. > > What Happens With Your Data > Your submissions are aggregated into a de-identified dataset. > No personal information gets shared with anyone. > The compiled data is presented to the physicians and researchers on the= =46DA advisory commission reviewing peptide classifications. > That's it. No middlemen. No commercial interests. No product to sell yo= u. Just community data going where it needs to go. > > =46inal Thoughts > The biggest threat to peptide access is the absence of organized data f= rom the people who actually use these compounds. > We have the community. We have the experience. We've just never had a s= ystem to capture it in a way that regulators take seriously. > Now we do. > If BPC-157 helped you heal a torn tendon, recover from gut issues, boun= ce back from surgery, or anything else, your experience is valuable evide= nce. Don't let it sit in your memory. Put it on record. > Submit your BPC-157 experience here > If you're a clinician who has prescribed or administered BPC-157, your = data carries even more weight. The form has a dedicated track for you. Pl= ease take five minutes and fill it out. > We're starting with BPC-157 because it's the most widely used and the m= ost immediately relevant to reclassification efforts. Other peptides will= follow. > Share this with anyone you know who has used BPC-157. Patients, provide= rs, training partners, anyone. The more data points we collect, the stron= ger the case becomes. > Thanks for being part of this=21 > Best, > Hunter Williams > > P.S. If you had a negative experience with BPC-157, that data is just a= s important. We are not cherry picking=21 Honesty is what gives this data= credibility with regulators. If we only show them the wins, they'll dism= iss the whole thing. We need the full picture. > Want more=3F Here=E2=80=99s how you can work with me: > =F0=9F=91=89Join my private coaching group, The AXION Collective: > > =E2=80=A2 > The AXION Collective > > =F0=9F=91=89Try Zeroats, the world=E2=80=99s first sugar-free, naturall= y flavored oatmeal: > > =E2=80=A2 > Store:=C2=A0https://zeroats.com/ > =E2=80=A2 > Amazon:=C2=A0https://a.co/d/2gq1zJ9 > > =F0=9F=91=89Link To All My Old Videos: > > =E2=80=A2 > DropBox with all videos > > =F0=9F=91=89Audio Versions of All Videos: > > =E2=80=A2 > Itunes > =E2=80=A2 > Spotify > > =F0=9F=91=89Get the Peptide Cheat Sheet: > > =E2=80=A2 > Peptide Cheat Sheet > > =F0=9F=91=89All my daily essentials on Amazon > > =E2=80=A2 > Amazon Storefront > > =F0=9F=91=89Get discounts on your favorite peptides and research chemic= als: > > =E2=80=A2 > PEPTIDES > =E2=80=A2 > BioLongevity Labs (use code hunterw for 15% off):=C2=A0= https://biolongevitylabs.com/ > > =F0=9F=91=8910% off the BEST workout supplements from Unmatched Supps (= pre-workout, whey protein, creatine, EAAs, electrolytes - use code HUNTER= W at checkout): > > =E2=80=A2 > https://www.unmatchedsupps.com=3Fsca=5Fref=3D8677061.S6mh8S= OsogBzjOO > > =F0=9F=91=89Submit A Video Topic =46or My Next YouTube Video: > > =E2=80=A2 > https://hunterwilliamsvideotopic.carrd.co/ > > Update your email preferences or unsubscribe here > =C2=A9 2026 Hunter's Health Hacks > 228 Park Ave S, =2329976, New York, New York 10003, United States > Powered by beehiiv > Terms of Service --69c5c159_107c1e2d_7d92 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline
---------- =46orwarded message ----= ------
=46rom: Hunter Williams <huntershealthhacks=40mail.beehiiv.com&= gt;
Date: Mar 26, 2026 at 6:02=E2=80=AFPM -0400
To: tjphuhs=40gmail.com <tjphuhs=40gmail.com>
Subject: Your BPC-157 Experience Could Change =46DA policy

Just 5 mi= nutes of your time &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23= 160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2= =80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C= &=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=23160;=E2=80=8C&=231= 60;=E2=80=8C&=23160;=E2=80=8C

March 26, 2026 &=23160; =7C &=23160; Read online

Your BPC-157 Experience Could Change =46DA p= olicy

Just 5 minutes of your time
3D=22share
&=23160;
3D=22share
&=23160;
3D=22share
&=23160;
3D=22share
3D=22=22

Happy Thursday=21

The =46DA classified BPC-157 as a Category 2 bulk drug substanc= e in 2023.

Their reasoning=3F Insufficient evidence on whether it causes h= arm to humans.

Meanwhile, hundreds of thousands of people have used BPC-157, i= ncluding many of you reading this right now. And most of you walked away = with zero adverse events and a healed injury.

But as of now, we have no documented way to verify the safety a= nd efficacy of some of the most common and effective peptides.

=

Well, hopefully that=E2=80=99s about to change.
&=23160;

The Project

I've been working on something behind the scenes with a team of= heavy hitters that I'm finally ready to share with you.

It's called the Peptide Safety Initiative.

The =46DA says there isn't enough human safety data on BPC-157 = to justify allowing compounding pharmacies to produce it. The published c= linical data are razor-thin. One small pilot study. A couple of retrospec= tive case reviews. No large-scale human trials.

But what does the =46DA not have access to=3F

Your experience.

The real-world experience of the thousands of people who have u= sed BPC-157 for gut healing, tendon repair, joint recovery, post-surgical= rehab, and everything in between.

That gap between what regulators see on paper and what our comm= unity has experienced firsthand is the entire problem.

So we built a tool to close that gap.
&=23160;

The Peptide Safety Initiative

We created a structured reporting platform where you can docume= nt your personal experience with BPC-157. The data gets aggregated and de= -identified. Then it goes directly to the doctors and researchers working= with the =46DA on peptide reclassification.

This is a real-world evidence collection effort modeled after t= he kind of data regulatory bodies actually take seriously.

There is a commission currently reviewing the Category 2 design= ation for several peptides.

The doctors on that commission need volume.

They need to show the =46DA that real humans have used this com= pound, here's what happened, and here's the safety profile across a large= population.

Good, bad, or neutral. All of it matters.
&=23160;

What You'll Be Asked

The form takes a few minutes. There are two tracks.

If you're a clinician or prescriber, you'll document your professional experience wi= th BPC-157 across your patient population.

Clinical indications you treated. Objective outcomes you observ= ed. Routes of administration, dosing protocols, duration of use, and sour= cing.

There's a dedicated adverse event reporting section covering in= jection site reactions, fluid retention, hypoglycemia symptoms, cardiac c= hanges, neuropsychiatric effects, GI issues, and blood pressure fluctuati= ons.

You'll also rate the overall safety profile on a 0 to 10 scale = based on your clinical judgment.

If you're an individual user, you'll share basic demographics (age, sex, height, wei= ght, ethnicity), what your goal was for using BPC-157, what results you e= xperienced, your dosing details, and where you sourced it.

You'll go through the same adverse event checklist covering inj= ection site reactions, swelling, hypoglycemia symptoms, heart rate change= s, mood effects, GI distress, and blood pressure changes. You'll rate ove= rall safety on the same 0 to 10 scale.

Both tracks ask whether you discontinued use due to side effect= s. And both give you space to share additional details like lab values, i= maging findings, or recovery stories.

Everything is voluntary. Everything is anonymous.
&=23160;

Why This Matters

The regulatory landscape around peptides is shifting fast. Ther= e are people inside the system right now who are willing to fight for rec= lassification. But they need ammunition.

Anecdotes in a Reddit thread don't move regulatory bodies, but = structured, aggregated real-world evidence from hundreds or thousands of = people does.

Think about what we're up against.

The =46DA's position is that there's not enough human data. Tha= t's technically true when you look at published clinical trials. But it c= ompletely ignores the massive real-world evidence base sitting inside thi= s community.

We can change that. But only if enough people participate.
&=23160;

What Happens With Your Data

Your submissions are aggregated into a de-identified dataset.

No personal information gets shared with anyone.

The compiled data is presented to the physicians and researcher= s on the =46DA advisory commission reviewing peptide classifications.

That's it. No middlemen. No commercial interests. No product= to sell you. Just community data going where it needs to go.<= /p>

&=23160;

=46inal Thoughts

The biggest threat to peptide access is the absence of organize= d data from the people who actually use these compounds.

We have the community. We have the experience. We've just never= had a system to capture it in a way that regulators take seriously.

Now we do.

If BPC-157 helped you heal a torn tendon, recover from gut issu= es, bounce back from surgery, or anything else, your experience is valuab= le evidence. Don't let it sit in your memory. Put it on record.

Submit= your BPC-157 experience here

If you're a clinician who has prescribed or administered BPC-15= 7, your data carries even more weight. The form has a dedicated track for= you. Please take five minutes and fill it out.

We're starting with BPC-157 because it's the most widely used a= nd the most immediately relevant to reclassification efforts. Other pepti= des will follow.

Share this with anyone you know who has used BPC-157. Patients,= providers, training partners, anyone. The more data points we collect, t= he stronger the case becomes.

Thanks for being part of this=21

Best,

Hunter Williams
&=23160;

P.S. If you= had a negative experience with BPC-157, that data is just as important. = We are not cherry picking=21 Honesty is what gives this data credibility = with regulators. If we only show them the wins, they'll dismiss the whole= thing. We need the full picture.
3D=22ig=22 3D=22=

Want more=3F Here=E2=80=99s= how you can work with me:

=F0=9F=91=89Join my private= coaching group, The AXION Collective:

=F0=9F=91=89Try Zeroats, th= e world=E2=80=99s first sugar-free, naturally flavored oatmeal:

=F0=9F=91=89Get the Peptide= Cheat Sheet:

=F0=9F=91=89All my daily es= sentials on Amazon

=F0=9F=91=89Get discounts o= n your favorite peptides and research chemicals:

=F0=9F=91=8910% off the BES= T workout supplements from Unmatched Supps (pre-workout, whey protein, cr= eatine, EAAs, electrolytes - use code HUNTERW at checkout):

=F0=9F=91=89Submit A Video = Topic =46or My Next YouTube Video:

Update your email preferences or unsubscribe here

=C2=A9 2026 Hunter's Health Hacks

228 Park Ave S, =2329976, New York, New York 10003, United S= tates
3D=22beehiivPow= ered by beehiiv
Terms of Service
--69c5c159_107c1e2d_7d92--